Chimeric Antigen Receptor Modified T Cells Infusion
Lymphoproliferative Disorders
UNC Lineberger Comprehensive Cancer CenterCell therapyPhase 1/2Active
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 40/ 100
- Competitive Position
- 89/ 100
Competitive context
18 Active assets in the Lymphoproliferative Disorders cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Beijing Immunochina Medical Science & Technology Co., Ltd. | Phase 2 | BB |
Tabelecleucel Pierre Fabre Medicament | Phase 3 | BB |
Ibrutinib Oncternal Therapeutics, Inc | Phase 3 | B |
Zilovertamab Oncternal Therapeutics, Inc | Phase 3 | B |
ALECTINIB Cancer Research UK | Phase 2/3 | B |
View all 34 →
Same molecule, other indications
Chimeric Antigen Receptor Modified T Cells Infusion is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →